Almirall, S.A. (VIE:ALM)

Market Cap	2.47B +16.1%
Revenue (ttm)	1.11B +12.5%
Net Income	46.15M +354.9%
EPS	0.22 +354.9%
Shares Out	n/a
PE Ratio	53.42
Forward PE	27.49
Dividend	0.15 (1.27%)
Ex-Dividend Date	May 15, 2025

Volume	n/a
Average Volume	n/a
Open	11.32
Previous Close	11.40
Day's Range	11.32 - 11.40
52-Week Range	8.68 - 13.84
Beta	n/a
RSI	28.51
Earnings Date	Feb 23, 2026

About Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys...

• Industry: Pharmaceutical Preparations
• Founded: 1943
• Employees: 2,108
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: ALM

Financial Performance

In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.